Results 21 to 30 of about 7,390 (165)

Case Report: Rapid Desensitization to Ocrelizumab for Multiple Sclerosis Is Effective and Safe

Frontiers in Immunology, 2022
Monoclonal antibodies have become a mainstay of treatment for many inflammatory diseases and malignancies. Multiple sclerosis is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system and a common cause of ...
Marcelo Vivolo Aun, Marcelo Vivolo Aun, Fernando Freua, Fernando Freua, Victor Hugo Rocha Marussi, Pedro Giavina-Bianchi   +5 more
doaj   +1 more source

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy

Neurology and Therapy, 2023
Background Some multiple sclerosis (MS) disease-modifying therapies (DMTs) impair responses to vaccines, emphasizing the importance of understanding COVID-19 vaccine immune responses in people with MS (PwMS) receiving different DMTs.
Aliya Jaber, Meera Patel, Andrew Sylvester, Mary Yarussi, J. Tamar Kalina, Jason P. Mendoza, Robin L. Avila, Matthew A. Tremblay   +7 more
doaj   +1 more source

Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study

BMJ Neurology Open, 2021
Background To monitor long-term outcomes of ocrelizumab treatment.Objective To evaluate safety and treatment outcomes of ocrelizumab in a community-based multiple sclerosis (MS) population.Methods Adult patients with MS prescribed ocrelizumab were ...
Kyle Smoot, Chiayi Chen, Tamela Stuchiner, Lindsay Lucas, Lois Grote, Stanley Cohan   +5 more
doaj   +1 more source

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023
Background In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label).
Ide Smets, Matthijs Versteegh, Simone Huygens, Cato Corsten, Beatrijs Wokke, Joost Smolders   +5 more
doaj   +1 more source

Ocrelizumab in Multiple Sclerosis: A Real-World Study From Spain

Frontiers in Neurology, 2021
Objectives: The aim of this study was to describe the tolerability, safety, and effectiveness of ocrelizumab for primary progressive multiple sclerosis (PPMS) and relapsing multiple sclerosis (RMS) in a clinical practice setting.Methods: In this ...
Angel P. Sempere, Angel P. Sempere, Leticia Berenguer-Ruiz, Ines Borrego-Soriano, Amparo Burgos-San Jose, Luis Concepcion-Aramendia, Lucian Volar, Miguel Aragones, Antonio Palazón-Bru   +8 more
doaj   +1 more source

Severe late‐onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report

Clinical Case Reports, 2022
Ocrelizumab is a recombinant humanized antibody targeted against CD‐20 molecule, which was approved for the treatment of relapsing and primary progressive multiple sclerosis.
Robin Rauniyar, Rahul Rauniyar, Ankita Agrawal, Shikha Yadav, Sreekant Avula   +4 more
doaj   +1 more source

Ocrelizumab vid behandling av multipel skleros

Objective: The aim of this study is to thoroughly evaluate the effects of ocrelizumab as a treatment for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS).
Samer Saleh, Batol
core   +4 more sources

Safety and patient experience with at‐home infusion of ocrelizumab for multiple sclerosis

Annals of Clinical and Translational Neurology, 2023
Objective This study aimed to evaluate safety (infusion‐related reactions [IRRs]) and patient satisfaction (patient‐reported outcomes [PROs]) for at‐home ocrelizumab administration for patients with multiple sclerosis (MS).
Britney Barrera, Haley Simpson, Eric Engebretson, Stefan Sillau, Brooke Valdez, José Parra‐González, Ryan C. Winger, Lou Anne Epperson, Ashley Banks, Kathryn Pierce, Melanie Spotts, Katie O'Gean, Enrique Alvarez, Robert Gross, Amanda L. Piquet, Teri Schreiner, John R. Corboy, Jinglan Pei, Timothy L. Vollmer, Kavita V. Nair   +19 more
doaj   +1 more source

Ocrelizumab: A Review in Multiple Sclerosis

, 2022
DeclarationsFunding The preparation of this review was not supported by any external funding.Authorship and Conflict of interest Yvette Lamb is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest.
Yvette Lamb (6930427)
core   +1 more source

Anti-JCV antibody index does not change during ocrelizumab-treatment

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020
Objective To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients. Methods Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin ...
Torge Rempe, Aaron Carlson, Augusto Miravalle, Tirisham Victoria Gyang   +3 more
doaj   +1 more source